New Option For Uncontrolled Epilepsy On Horizon As US Accepts Cenobamate NDA

New potentially effective therapy for drug-resistant epilepsy, seen as the most pressing unmet need in this market, is on the horizon as FDA begins approval review of SK’s cenobamate, also marking a first for the Korean pharma industry.